SavedAdd your journal

Journals / Marmara Medical Journal / 2026 / Volume: 21 Issue: 1

-

75 YAŞ VE ÜZERİ LOKAL İLERİ VE METASTATİK KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE PRİMER VE PALYATİF TEDAVİ OLARAK RADYOTERAPİ UYGULAMASI: 45 VAKANIN DEĞERLENDİRİLMESİ VE LİTERATÜR İNCELEMESİ

Görkem Aksu
Merdan Fayda
Mert Saynak
Esra Kaytan Saglamer
Ethem Nezih Oral
Ahmet Kizir
Ahmet Karadeniz
Pages
—
Publication Date
2015-06-23
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Amaç: Lokal ileri veya metastatik KHDAK tanılı hastalarda prognostik faktörler ve tedavi sonuçlarının değerlendirilmesi Hastalar ve Yöntem: Yetmiş beş yaş ve üzeri toplam 45 KHDAK tanılı hasta değerlendirildi. Medyan yaş 78 idi (75-93). Otuz dört hasta Evre IIIB (75%), 11 hasta (25%) ise Evre IV olarak evrelendirildi. Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.

🔖

Cite This Article

Aksu, G., Fayda, M., Saynak, M., Saglamer, E. K., Oral, E. N., Kizir, A., Karadeniz, A. (2015). -. Marmara Medical Journal, Volume: 21 Issue: 1. https://ajindex.com/articles/1287082

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (113)

  1. Lonardi F, Coeli M, Pavanato G, Adami F, Gioga G,
  2. Campostrini F. Radiotherapy for non-small cell lung
  3. cancer in patients aged 75 and over, safety, effectiveness
  4. and possible impact on survival. Lung Cancer 2000; 28:
  5. Tombolini V, Bonanni A, Donato V, et al. Radiotherapy
  6. alone in elderly patients with medically inoperable stage
  7. IIIA and IIIB non-small cell lung cancer. Anticancer Res; 20,:4829-4833.
  8. Rengan R, Rosenzweig, KE, Venkatraman E, et al.
  9. Improved local control with higher doses of radiation in
  10. large-volume stage III non-small-cell lung cancer. Int J
  11. Radiat Oncol Biol Phys 2004;60:741-747.
  12. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Longterm
  13. survivors in metastatic non-small cell lung cancer:
  14. an Eastern Cooperative Oncology Group Study. J Clin
  15. Oncol 1986;4:702–709.
  16. Albain KS, Crowley JJ, LeBlanc M, Livingston RB.
  17. Survival determinants in extensive-stage non-small cell
  18. lung cancer: the Southwest Oncology Group experience.
  19. J Clin Oncol 1991; 9: 1618–1626.
  20. Borges, M., Sculier, JP., Paesmans, M., et al. Prognostic
  21. factors for response to chemotherapy containing
  22. platinum derivatives in patients with unresectable nonsmall
  23. cell lung cancer (NSCLC). Lung Cancer 1996;16:
  24. Stanley, KE. Prognostic factors for survival in patients
  25. with inoperable lung cancer. J Natl Cancer Inst;65:25–32.
  26. Hillner BE, McDonald MK, Desch CE, Smith TJ,
  27. Penberthy L, Retchin SM. A comparison of patterns of
  28. care of nonsmall cell lung carcinoma patients in a
  29. younger and Medigap commercially insured cohort.
  30. Cancer 1998;83: 1930–1937.
  31. Smith TJ, Penberthy L, Desch CE, et al. Differences in
  32. initial treatment patterns and outcomes of lung cancer in
  33. the elderly. Lung Cancer 1995;13:235–252.
  34. Jeremic B, Shibamoto Y. Pre-treatment prognostic
  35. factors in patients with stage III non-small cell lung
  36. cancer treated with hyperfractionated radiation therapy
  37. with or without concurrent chemotherapy. Lung Cancer; 13: 21–30.
  38. Langer C, Hsu C, Curran D, et al. Do elderly patients
  39. with locally advanced non-small cell lung cancer benefit
  40. from combined modality therapy? A secondary analysis
  41. of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51:
  42. Gauden SJ, Tripcony L. The curative treatment by
  43. radiation therapy alone of Stage I non- small cell lung
  44. cancer in a geriatric population. Lung Cancer 2001; 32:
  45. Sause W, Kolesar P, Taylor SI, et al. Final results of
  46. phase III trial in regionally advanced unresectable nonsmall
  47. cell lung cancer: Radiation Therapy Oncology
  48. Group, Eastern Cooperative Oncology Group, and
  49. Southwest Oncology Group. Chest 2000; 117: 358–364.
  50. Newman AB, Yanez D, Harris T, et al. Weight change
  51. in old age and its association with mortality. J Am
  52. Geriatr Soc 2001; 49: 1309–1318.
  53. Movsas B, Scott C, Sause W, et al. The benefit of
  54. treatment intensification is age and histology-dependent
  55. in patients with locally advanced non-small cell lung
  56. cancer (NSCLC): a quality-adjusted survival analysis of
  57. radiation therapy oncology group (RTOG)
  58. chemoradiation studies. Int J Radiat Oncol Biol Phys; 45: 1143–1149.
  59. Numico G, Russi E, Merlano M. Best supportive care in
  60. non-small cell lung cancer: Is there a role for
  61. radiotherapy and chemotherapy? Lung Cancer 2001; 32:
  62. Chemotherapy in non-small cell lung cancer: a metaanalysis
  63. using updated data on individual patients from
  64. randomized clinical trials. Non-small Cell Lung
  65. Cancer Collaborative Group. BMJ 1995; 311: 899–909.
  66. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of
  67. chemotherapy for advanced lung cancer in the elderly:
  68. instrumental variable and propensity analysis. J Clin
  69. Oncol 2001; 19: 1064–1070.
  70. Effects of vinorelbine on quality of life and survival of
  71. elderly patients with advanced non-small cell lung
  72. cancer. The Elderly Lung Cancer Vinorelbine Italian
  73. Study Group. J Natl Cancer Inst 1999; 91: 66–72.
  74. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for
  75. cancer: the Multicenter Italian Lung Cancer in the
  76. Elderly Study (MILES) phase III randomized trial. J
  77. Natl Cancer Inst 2003, 95: 362–372.
  78. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus
  79. vinorelbine versus vinorelbine alone in elderly patients
  80. with advanced non-small cell lung cancer. J Clin Oncol; 18: 2529–2536.
  81. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based
  82. therapy for elderly patients with advanced non-small cell
  83. lung cancer: implications of Eastern Cooperative
  84. Oncology Group 5592, a randomized trial. J Natl Cancer
  85. Inst 2002; 94: 173–181.
  86. Kelly K, Giarritta S, Akerley W, et al. Should older
  87. patients (Pts) receive combination chemotherapy for
  88. advanced stage non-small cell lung cancer (NSCLC)?
  89. An analysis of Southwest Oncology Trials 9509 and
  90. Proc Am Soc Clin Oncol 2001; 20: 329a.
  91. Hensing TA, Socinski MA, Schell MJ, et al. Age does
  92. not alter toxicity or survival for patients (pts) with stage
  93. IIIB/IV non-small cell lung cancer (NSCLC) treated
  94. with carboplatin (C) and paclitaxel (P). Proc Am Soc
  95. Clin Oncol 2001; 20: 346a.
  96. Lilenbaum RC, Herndon J, List M, et al. Single-agent
  97. (SA) versus combination chemotherapy (CC) in
  98. advanced non-small cell lung cancer (NSCLC): a
  99. CALGB randomized trial of efficacy, quality of life
  100. (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol; 21: 1a.
  101. Marmara Medical Journal 2008;21(1);011-020
  102. Görkem Aksu, et al.
  103. Radiotherapy as the primary and palliative treatment for patients aged 75 or over with locally advanced and metastatic
  104. Non-Small Cell Lung Cancer: Analysis of 45 cases with a review of the literature
  105. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of
  106. ZD1839 (‘Iressa’) in advanced non-small cell lung
  107. cancer (NSCLC) patients who had failed platinum- and
  108. docetaxel-based regimens (IDEAL 2). Proc Am Soc
  109. Clin Oncol 2002; 21: 292a
  110. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional
  111. randomized phase II trial of gefitinib for
  112. previously treated patients with advanced non-small cell
  113. lung cancer. J Clin Oncol 2003; 21: 2237–2246.